MedPage Today reported on a new, retrospective study involving Kyprolis over the weekend. It makes my myeloma specialist, Dr. Tricot, look pretty smart for using Kyprolis as part of my three drug post transplant consolidation therapy.
An amazing over-the-top (pun intended) multiple myeloma awareness and fundraising mountain climbing adventure scaling Mr. Kilimanjaro sponsored by the MMRF:
I’m part of a Cure Talk Radio broadcast in a few hours featuring Multiple Myeloma Research Foundation co-founder, Anne Quinn Young. If you can’t listen live, I’ll pass along a link so you an listen later.
A lot has happened since I ran two of the final installments about the importance of controlling blood glucose by Danny Parker:
Blood Glucose, MGUS, Myeloma & Metformin (Part Seven and Eight)
How much money would it take to cure multiple myeloma? 50 million? 100 million? With some off-the-charts luck, we’ll know in just over an hour. For the first time ever, I’m playing Powerball. The one time payout on the 1.5 billion dollar jackpot: 930 million dollars.
Monday morning my email inbox lit up. A Wall Street Journal article–both online and in the hard copy edition–about the FDA’s unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center.
New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid.
Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.
Another exciting, new immunotherapy may be on the horizon: Keytruda
ASH, unscheduled trips to the ICU, Iowa City drama. A lot has happened since I ran the last installment of Danny Parker’s series about blood glucose and metformin.
Last week I had the opportunity to interview the Senior Director of Clinical Research for Janssen Pharmaceuticals, Dr. Tahamtan Ahmadi, PhD. Janssen is the company that manufacturers newly FDA approved Darzalex (daratumumab). I promised a more detailed follow up and I’m glad to follow through.
Before I pass along important information about Takeda’s new oral proteasome inhibitor, Ninlaro (ixazomib), I wanted to share an update about how I’m doing.
Data for more than a dozen “new” myeloma drugs was presented at this week’s American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers.
I’m accumulating way too much information for me to process and pass along right away. I’m still waiting on company verified combination data for Darzalex/Pomalyst/dex. I’ll also have updated stats for ongoing elotuzumab and ARRY-520 trials. In the meantime, I interviewed Dr. Thorsten Graef, the Head of Hematology and Global Medical Safety for pharmacyclics, a […]
As promised, here are details from a preliminary study showing impressive response rates when Darzalex (daratumumab) is combined with Revlimid and dexamethasone.
Happy Myeloma Monday! I’m not sure how or why the tradition began, but for the seven years I’ve been coming to ASH, Monday has always been the biggest myeloma news day.
I’m here at the American Society of Hematology (ASH) meetings in Orlando, helping CrowdCare Foundation founder, Jenny Ahlstrom. The big news here today focused on an impressive breakthrough in T cell therapy.
I’m almost packed. Tomorrow I’ll be driving three hours south to Orlando to attend my 7th American Society of Hematology (ASH) annual meeting. Seven years! How the multiple myeloma therapy landscape has changed. Heck, things have been turned upside down in three short weeks.
I wanted to squeeze in another of Danny Parker’s important columns before things get too busy right before ASH. He shifts gears, beginning to focus on clinical trials and the future of multiple myeloma research.
In my haste to get the news out about elotuzumab’s FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone […]